On Jul. 29, 2021, SIGA Technologies announced that it had entered into a collaboration with Oxford University in the United Kingdom to provide TPOXX (tecovirimat) under an expanded access protocol to treat individuals affected by monkeypox in the Central African Republic (CAR).

Under the agreement, Oxford University sponsor the protocol and study in CAR, and SIGA provided up to 500 courses of TPOXX (tecovirimat) at no cost.